CN114845711B - Raf激酶的抑制剂 - Google Patents

Raf激酶的抑制剂 Download PDF

Info

Publication number
CN114845711B
CN114845711B CN202080090257.4A CN202080090257A CN114845711B CN 114845711 B CN114845711 B CN 114845711B CN 202080090257 A CN202080090257 A CN 202080090257A CN 114845711 B CN114845711 B CN 114845711B
Authority
CN
China
Prior art keywords
carboxamide
trifluoroethyl
pyrrolidine
methylphenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080090257.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114845711A (zh
Inventor
史蒂芬·W·卡尔多
陶菲克·卡努尼
约翰·泰霍纳斯
埃里克·A·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA, Jinnaite Biopharmaceutical Co filed Critical Pierre Fabre Medicament SA
Publication of CN114845711A publication Critical patent/CN114845711A/zh
Application granted granted Critical
Publication of CN114845711B publication Critical patent/CN114845711B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080090257.4A 2019-10-24 2020-10-23 Raf激酶的抑制剂 Active CN114845711B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925596P 2019-10-24 2019-10-24
US62/925,596 2019-10-24
US202063044898P 2020-06-26 2020-06-26
US63/044,898 2020-06-26
PCT/US2020/057132 WO2021081375A1 (en) 2019-10-24 2020-10-23 Inhibitors of raf kinases

Publications (2)

Publication Number Publication Date
CN114845711A CN114845711A (zh) 2022-08-02
CN114845711B true CN114845711B (zh) 2024-10-01

Family

ID=75619376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090257.4A Active CN114845711B (zh) 2019-10-24 2020-10-23 Raf激酶的抑制剂

Country Status (16)

Country Link
US (3) US11098031B1 (cg-RX-API-DMAC7.html)
EP (1) EP4048259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7626910B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220104702A (cg-RX-API-DMAC7.html)
CN (1) CN114845711B (cg-RX-API-DMAC7.html)
AU (1) AU2020371727B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158530A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000998A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006712A2 (cg-RX-API-DMAC7.html)
IL (1) IL292424B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004937A (cg-RX-API-DMAC7.html)
PH (1) PH12022550976A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899110B (cg-RX-API-DMAC7.html)
WO (1) WO2021081375A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204284B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) * 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US20230046018A1 (en) * 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022060996A1 (en) * 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) * 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) * 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
US20240327343A1 (en) * 2021-07-19 2024-10-03 Kinnate Biopharma Inc. Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride
CN115974851A (zh) * 2021-10-14 2023-04-18 华领医药技术(上海)有限公司 2-氧代-3-氮杂双环[3.1.0]己烷衍生物
WO2023070053A1 (en) * 2021-10-21 2023-04-27 Kinnate Biopharma Inc. Inhibitors of raf kinases
AU2022405115A1 (en) * 2021-12-09 2024-07-11 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
TW202342055A (zh) 2022-02-03 2023-11-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
US20250171462A1 (en) * 2022-03-02 2025-05-29 Nico Therapeutics, Inc. Compounds, compositions, and methods
US20260100247A1 (en) * 2022-09-30 2026-04-09 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2844211T3 (es) 2014-09-12 2021-07-21 Novartis Ag Compuestos y composiciones en calidad de inhibidores de quinasa
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6636014B2 (ja) * 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
BR112018075371A2 (pt) 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN113874381A (zh) * 2019-03-22 2021-12-31 金耐特生物制药公司 Raf激酶的抑制剂

Also Published As

Publication number Publication date
MX2022004937A (es) 2022-07-27
US11098031B1 (en) 2021-08-24
EP4048259A1 (en) 2022-08-31
EP4048259A4 (en) 2023-08-02
AU2020371727B2 (en) 2026-01-22
JP7626910B2 (ja) 2025-02-05
US20260055084A1 (en) 2026-02-26
TW202128680A (zh) 2021-08-01
CA3158530A1 (en) 2021-04-29
BR112022007612A2 (pt) 2022-09-20
PH12022550976A1 (en) 2023-09-25
IL292424B2 (en) 2026-06-01
NZ788005A (en) 2024-10-25
IL292424B1 (en) 2026-02-01
CN114845711A (zh) 2022-08-02
KR20220104702A (ko) 2022-07-26
TWI899110B (zh) 2025-10-01
IL292424A (en) 2022-06-01
CO2022006712A2 (es) 2022-05-31
JP2022554169A (ja) 2022-12-28
CL2022000998A1 (es) 2023-02-10
ZA202204284B (en) 2024-09-25
US12312336B2 (en) 2025-05-27
WO2021081375A1 (en) 2021-04-29
AU2020371727A1 (en) 2022-05-26
US20210300904A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2020371727B2 (en) Inhibitors of RAF kinases
KR20250095617A (ko) 신규한 트리헤테로사이클릭 화합물{Novel triheterocyclic compounds}
TW202231633A (zh) Cdk抑制劑
EP3442947A1 (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
JP2021529740A (ja) サイクリン依存性キナーゼの阻害剤
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
CN113874381A (zh) Raf激酶的抑制剂
JP7253086B2 (ja) アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
CN120548308A (zh) Kif18a的抑制剂及其用途
EP4072679A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2024102621A1 (en) Akt1 modulators
CA3246087A1 (en) HETEROCYCLIC COMPOUNDS AS BCL6 MODULATORS FOR USE AS DEGRADING AGENTS DIRECTED AGAINST A LIGAND
BR112020010012A2 (pt) compostos de pirazolopiridinona
JP7349570B2 (ja) M4作動薬としての2-アザスピロ[3.4]オクタン誘導体
CN116322692A (zh) 自分泌运动因子抑制剂化合物
TW202204342A (zh) N—(雜環基及雜環基烷基)—3—苯甲基吡啶—2—胺衍生物
JP2022551853A (ja) M4作動薬としての5-オキサ-2-アザスピロ[3.4]オクタン誘導体
CN119156385A (zh) 稠合双环杂芳族化合物及其在治疗癌症中的用途
HK40077347A (zh) Raf激酶的抑制剂
HK40063842A (en) Inhibitors of raf kinases
HK40077347B (en) Inhibitors of raf kinases
EA052498B1 (ru) Гетероциклические соединения в качестве модуляторов bcl6 как лиганд-направленных деградеров

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077347

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240906

Address after: Laval, France

Applicant after: PIERRE FABRE MEDICAMENT

Country or region after: France

Address before: California, USA

Applicant before: Jinnaite biopharmaceutical Co.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant